Annals of Surgical Oncology

, Volume 18, Supplement 3, pp 281–282 | Cite as

Moving Away From Axillary Lymph Node Dissection Indicates Practice-Changing Trials

Breast Oncology

References

  1. 1.
    Weaver DL, Ashikaga T, Krag DN, et al. 2011 Effect of occult metastases on survival in node-negative breast cancer. N Engl J Mecancerd. 2011;364(5):412–21CrossRefGoogle Scholar
  2. 2.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.Google Scholar
  3. 3.
    Caudle AS, Hunt KK, Kuerer HM, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Feb 15 [Epub ahead of print].Google Scholar
  4. 4.
    King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011 Apr 4 [Epub ahead of print].Google Scholar
  5. 5.
    Green ED, Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Per Med. 2010;7(4):347–50.CrossRefGoogle Scholar
  7. 7.
    Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11(2):81–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Katsios C, Roukos DH. Missing heritability, next-generation genome-wide association studies and primary cancer prevention: an Atlantean illusion? Future Oncol. 2011;7(4):477–80.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital of Ioannina, School of MedicineIoanninaGreece
  2. 2.Department of General SurgeryUniversity Hospital of Heraklion, Medical School, University of Crete HeraklionCreteGreece

Personalised recommendations